6-EAPB, also known as 6-(2-aminopropyl)benzofuran, is a designer drug that belongs to the benzofuran family. It was first synthesized in 1993 and has been reported to have stimulant and empathogenic effects. The chemical structure of 6-EAPB is similar to that of MDA, a popular recreational drug.
6-EAPB has a relatively short history compared to other designer drugs. It was first synthesized by a team of researchers at Pfizer in the early 1990s. However, it was never marketed as a pharmaceutical drug due to its psychoactive effects. It was later rediscovered by the research chemical community in the mid-2000s and has since become popular among recreational drug users.
6-EAPB is a white powder that is soluble in organic solvents. It has a molecular weight of 203.28 g/mol and a melting point of 176-178 °C. It is a benzofuran derivative and has a similar chemical structure to other empathogenic drugs like MDMA.
The effects of 6-EAPB are similar to those of other empathogenic drugs. It is reported to produce feelings of empathy, euphoria, and increased sociability. Users have also reported enhanced tactile sensations and music appreciation. The onset of effects is typically within 30-45 minutes of ingestion, with peak effects occurring around 2-3 hours after ingestion. The duration of effects can last anywhere from 4-8 hours.
As with any psychoactive substance, 6-EAPB can produce side effects. These can include increased heart rate, elevated blood pressure, sweating, and dilated pupils. Other reported side effects include anxiety, paranoia, and insomnia. However, the overall risk of serious side effects is relatively low when used responsibly.
6-EAPB is not approved for human consumption and is classified as a designer drug. Its legal status varies by country, but it is generally considered a controlled substance. In Sweden, for example, it is classified as a hazardous substance and possession or distribution is punishable by law.
In summary, 6-EAPB is a designer drug with stimulant and empathogenic effects. It was first synthesized in the early 1990s and has since become popular among recreational drug users. While it can produce side effects, the overall risk of serious harm is relatively low when used responsibly. However, it is important to note that 6-EAPB is not approved for human consumption and is considered a controlled substance in many countries.